Business Context and Reporting Period
Syndax Pharmaceuticals Inc. (SNDX) filed a Form 8-K on October 7, 2019, to disclose a significant clinical trial update under Regulation FD. The company is an emerging growth corporation focused on developing novel therapies for cancer.
Key Financial Metrics
This filing is a current report regarding a clinical milestone and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Update
- Event: The ECOG-ACRIN Cancer Research Group notified Syndax that the Phase 3 registration trial (E2112) for entinostat plus exemestane in advanced HR+, HER2- breast cancer has passed its fifth and final interim overall survival (OS) analysis.
- Next Steps: The trial will continue until the final OS analysis is triggered by the occurrence of 410 deaths among the 608 enrolled patients.
- Timeline: Based on modeling of the assumed event rate, the company expects the final analysis to occur in the second quarter of 2020.
- Background: The trial design was informed by the Phase 2b ENCORE 301 trial, which demonstrated a strong OS benefit and led to entinostat's Breakthrough Therapy designation.
Guidance, Outlook, and Risks
Management provided a specific timeline expectation for the final data readout (Q2 2020) based on internal modeling. The filing notes that the information, including the attached corporate presentation (Exhibit 99.1), is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings. No specific financial risks or contingencies were detailed in this text.
Investor Verification Checklist
- Verify the status of the E2112 trial on the clinicaltrials.gov registry or via the ECOG-ACRIN Cancer Research Group.
- Review the attached corporate presentation (Exhibit 99.1) for detailed statistical context regarding the interim analysis.
- Monitor future filings for the final OS analysis results expected in Q2 2020.
- Check the company's most recent 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not provide financial data.